210 related articles for article (PubMed ID: 2158362)
21. Synthesis and binding affinities of cyclic and related linear analogues of CCK8 selective for central receptors.
Charpentier B; Dor A; Roy P; England P; Pham H; Durieux C; Roques BP
J Med Chem; 1989 Jun; 32(6):1184-90. PubMed ID: 2724293
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis, and biological activities of cyclic lactam peptide analogues of dynorphine A(1-11)-NH2.
Lung FD; Collins N; Stropova D; Davis P; Yamamura HI; Porreca F; Hruby VJ
J Med Chem; 1996 Mar; 39(5):1136-41. PubMed ID: 8676350
[TBL] [Abstract][Full Text] [Related]
23. 14-membered cyclic opioids related to dermorphin and their partially retro-inverso modified analogues. I. Synthesis and biological activity.
Said-Nejad OE; Felder ER; Mierke DF; Yamazaki T; Schiller PW; Goodman M
Int J Pept Protein Res; 1992 Feb; 39(2):145-60. PubMed ID: 1517014
[TBL] [Abstract][Full Text] [Related]
24. Conformational-energy studies of tetrapeptide opiates. Candidate active and inactive conformations.
Loew G; Hashimoto G; Williamson L; Burt S; Anderson W
Mol Pharmacol; 1982 Nov; 22(3):667-77. PubMed ID: 7155126
[TBL] [Abstract][Full Text] [Related]
25. The mu- and delta-opioid pharmacophore conformations of cyclic beta-casomorphin analogues indicate docking of the Phe3 residue to different domains of the opioid receptors.
Brandt W; Stoldt M; Schinke H
J Comput Aided Mol Des; 1996 Jun; 10(3):201-12. PubMed ID: 8808737
[TBL] [Abstract][Full Text] [Related]
26. Dermorphin interaction with rat brain opioid receptors: involvement of hydrophobic sites in the binding domain.
Lazarus LH; Wilson WE; Guglietta A; de Castiglione R
Mol Pharmacol; 1990 Jun; 37(6):886-92. PubMed ID: 2163014
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and opioid activity of conformationally constrained dynorphin A analogues. 2. Conformational constraint in the "address" sequence.
Arttamangkul S; Ishmael JE; Murray TF; Grandy DK; DeLander GE; Kieffer BL; Aldrich JV
J Med Chem; 1997 Apr; 40(8):1211-8. PubMed ID: 9111295
[TBL] [Abstract][Full Text] [Related]
28. Development of a model for the delta opioid receptor pharmacophore. 2. Conformationally restricted Phe3 replacements in the cyclic delta receptor selective tetrapeptide Tyr-c[D-Cys-Phe-D-Pen]OH (JOM-13).
Mosberg HI; Omnaas JR; Lomize A; Heyl DL; Nordan I; Mousigian C; Davis P; Porreca F
J Med Chem; 1994 Dec; 37(25):4384-91. PubMed ID: 7996550
[TBL] [Abstract][Full Text] [Related]
29. Topochemical analysis of morphiceptin and dermorphin bioactivities.
Yamazaki T; Ro S; Goodman M
Biochem Biophys Res Commun; 1991 Dec; 181(2):664-70. PubMed ID: 1661586
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and biological evaluation of constrained analogues of the opioid peptide H-Tyr-D-Ala-Phe-Gly-NH2 using the 4-amino-2-benzazepin-3-one scaffold.
Ballet S; Frycia A; Piron J; Chung NN; Schiller PW; Kosson P; Lipkowski AW; Tourwé D
J Pept Res; 2005 Nov; 66(5):222-30. PubMed ID: 16218989
[TBL] [Abstract][Full Text] [Related]
31. The delta-selective opioid peptide dermenkephalin and the mu-selective hybrid peptide dermenkephalin-[1-4]-dermophin-[5-7] display strikingly different conformations despite identical tetrapeptide N-termini. A quantitative 2-D NMR and molecular modeling analysis.
Riand J; Baron D; Nicolas P; Benajiba A; Teng Y; Naim M
J Biomol Struct Dyn; 1999 Dec; 17(3):445-60. PubMed ID: 10636080
[TBL] [Abstract][Full Text] [Related]
32. Highly potent side chain-main chain cyclized dermorphin-deltorphin analogues: an integrated approach including synthesis, bioassays, NMR spectroscopy and molecular modelling.
Ro S; Zhu Q; Lee CW; Goodman M; Darlak K; Spatola AF; Chung NN; Schiller PW; Malmberg AB; Yaksh TL
J Pept Sci; 1995; 1(3):157-74. PubMed ID: 9222993
[TBL] [Abstract][Full Text] [Related]
33. Potent opioid peptide agonists containing 4'-[N-((4'-phenyl)-phenethyl)carboxamido]phenylalanine (Bcp) in place of Tyr.
Weltrowska G; Nguyen TM; Lemieux C; Chung NN; Schiller PW
Chem Biol Drug Des; 2008 Nov; 72(5):337-40. PubMed ID: 19012569
[TBL] [Abstract][Full Text] [Related]
34. Enkephalin analogues containing beta-naphthylalanine at the fourth position.
Mierke DF; Said-Nejad OE; Schiller PW; Goodman M
Biopolymers; 1990 Jan; 29(1):179-96. PubMed ID: 2158358
[TBL] [Abstract][Full Text] [Related]
35. Folded conformations of the delta-selective opioid dermenkephalin with head-to-tail interactions. A simulated annealing study through NMR restraints.
Naim M; Nicolas P; Baron D
Int J Pept Protein Res; 1996 May; 47(5):353-60. PubMed ID: 8791158
[TBL] [Abstract][Full Text] [Related]
36. Proposals for the mu-active conformation of the enkephalin analog Tyr-cyclol(-N gamma-D-A2-bu-Gly-Phe-Leu-).
Maigret B; Fournie-Zaluski MC; Roques B; Premilat S
Mol Pharmacol; 1986 Mar; 29(3):314-20. PubMed ID: 3005838
[TBL] [Abstract][Full Text] [Related]
37. Molecular dynamics simulations of opioid peptide analogs containing multiple conformational restrictions.
Wilkes BC; Schiller PW
Int J Pept Protein Res; 1992; 40(3-4):249-54. PubMed ID: 1478782
[TBL] [Abstract][Full Text] [Related]
38. Conformation-activity relationships of cyclo-constrained micro/delta opioid agonists derived from the N-terminal tetrapeptide segment of dermorphin/deltorphin.
Rodziewicz-Motowidło S; Czaplewski C; Luczak S; Ciarkowski J
J Pept Sci; 2008 Aug; 14(8):898-902. PubMed ID: 18338322
[TBL] [Abstract][Full Text] [Related]
39. N-terminal tetrapeptide of dermorphin and D-Arg-substituted tetrapeptides: inactivation process of the antinociceptive activity by peptidase.
Chaki K; Sakurada S; Sakurada T; Kisara K; Suzuki K
Life Sci; 1990; 46(23):1671-8. PubMed ID: 1972532
[TBL] [Abstract][Full Text] [Related]
40. New features of the delta opioid receptor: conformational properties of deltorphin I analogues.
Balboni G; Marastoni M; Picone D; Salvadori S; Tancredi T; Temussi PA; Tomatis R
Biochem Biophys Res Commun; 1990 Jun; 169(2):617-22. PubMed ID: 2162669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
